{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:24:22Z","timestamp":1790267062461,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Health Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The effects of antiseizure medications (ASMs) on cognitive functions have not been fully elucidated. The primary aim of this study was to demonstrate potential changes in cognitive functions in patients diagnosed with epilepsy from both neuropsychological and electrophysiological perspectives. Our secondary objective was to assess the effects of administered ASM on cognitive functions by categorizing patients into different monotherapy and polytherapy groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>A single-center, prospective patient registry study was conducted between May 2022 and June 2023. The inclusion criteria included epilepsy patients aged 18 to 50 years who were receiving ASM) treatment, either as inpatients or outpatients, and who did not have any syndromic diagnosis that may lead to cognitive disfunciton (such as primary progressive myoclonic epilepsies, Down syndrome and so on), and did not diagnosed previously or during examination that could affect dementia or cognitive functions. Patients who were scheduled to initiate new ASM treatment were evaluated using the Montreal Cognitive Assessment (MoCA) scale and Event-Related Potentials (ERP) assessment both before commencing treatment and three months thereafter.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 320 participants were included in the study; 20 healthy controls and 300 epilepsy patients were included. Statistically significant differences were observed between the healthy control group and the epilepsy group in terms of average Montreal Cognitive Assessment (MoCA) scores and event-related potentials (ERPs) (n200, p300 latencies, n2p3 amplitudes) (<jats:italic>p&lt;<\/jats:italic>0.05). Similarly, statistically significant differences were observed between the monotherapy and polytherapy groups in terms of average MoCA and ERP scores (<jats:italic>p&lt;<\/jats:italic>0.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study demonstrated the detrimental effects of certain ASMs, particularly topiramate and carbamazepine, on cognitive functions. Furthermore, the negative impact on cognitive performance became more pronounced with an increasing number of concurrently used ASMs (polytherapy), with topiramate showing notable effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10072-024-07606-5","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T12:01:55Z","timestamp":1716638515000},"page":"5011-5021","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The assessment of the impact of antiepileptic drugs on cognitive functions via N-200\/P-300 potentials and neuropsychological measures"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3334-979X","authenticated-orcid":false,"given":"Javid","family":"Shafiyev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer","family":"Karada\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"issue":"4","key":"7606_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1600-0404.2005.00485.x","volume":"112","author":"S Arroyo","year":"2005","unstructured":"Arroyo S, Dodson WE, Privitera MD, Glauser TA, Naritoku DK, Dlugos DJ, Wang S, Schwabe SK, Twyman RE (2005) Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 112(4):214\u2013222. https:\/\/doi.org\/10.1111\/j.1600-0404.2005.00485.x","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"7606_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000503831","volume":"54","author":"E Beghi","year":"2020","unstructured":"Beghi E (2020) The Epidemiology of Epilepsy. Neuroepidemiology 54(2):185\u2013191. https:\/\/doi.org\/10.1159\/000503831","journal-title":"Neuroepidemiology"},{"issue":"3\u20134","key":"7606_CR3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000493484","volume":"51","author":"E Beghi","year":"2018","unstructured":"Beghi E, Giussani G (2018) Aging and the Epidemiology of Epilepsy. Neuroendocrinology 51(3\u20134):216\u2013223. https:\/\/doi.org\/10.1159\/000493484","journal-title":"Neuroendocrinology"},{"key":"7606_CR4","doi-asserted-by":"publisher","unstructured":"Carre\u00f1o M, Donaire A, S\u00e1nchez-Carpintero R (2008) Cognitive disorders associated with epilepsy: Diagnosis and treatment. Neurologist 14(6 SUPPL. 1). https:\/\/doi.org\/10.1097\/01.nrl.0000340789.15295.8f","DOI":"10.1097\/01.nrl.0000340789.15295.8f"},{"issue":"11","key":"7606_CR5","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.clinph.2009.07.045","volume":"120","author":"CC Duncan","year":"2009","unstructured":"Duncan CC, Barry RJ, Connolly JF, Fischer C, Michie PT, N\u00e4\u00e4t\u00e4nen R, Polich J, Reinvang I, Van Petten C (2009) Event-related potentials in clinical research: Guidelines for eliciting, recording, and quantifying mismatch negativity, P300, and N400. Clin Neurophysiol 120(11):1883\u20131908. https:\/\/doi.org\/10.1016\/j.clinph.2009.07.045","journal-title":"Clin Neurophysiol"},{"issue":"3","key":"7606_CR6","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3233\/JAD-160979","volume":"56","author":"Z Ismail","year":"2017","unstructured":"Ismail Z, Ag\u00fcera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, Gauthier S, Geda YE, Herrmann N, Kanji J, Lanct\u00f4t KL, Miller DS, Mortby ME, Onyike CU, Rosenberg PB, Smith EE, Smith GS, Sultzer DL, Lyketsos C (2017) NPS Professional Interest Area of the International Society of to Advance Alzheimer\u2019s Research and Treatment (NPS-PIA of ISTAART). The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. J Alzheimers Dis 56(3):929\u2013938. https:\/\/doi.org\/10.3233\/JAD-160979","journal-title":"J Alzheimers Dis"},{"key":"7606_CR7","unstructured":"Fak\u00fcltesi T, Cilt K, Bayazit O (n.d.) Onur BAYAZIT Olay \u0130li\u015fkili Potansiyeller (O\u0130P). Tip Fak\u00fcltesi Klinikleri Dergisi 1(1):59\u201365"},{"key":"7606_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001417.pub2","volume-title":"Cochrane Database of Systematic Reviews","author":"N Jette","year":"2008","unstructured":"Jette N, Hemming K, Hutton JL, Marson AG (2008) Topiramate add-on for drug-resistant partial epilepsy. In: Jette N (ed) Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd. https:\/\/doi.org\/10.1002\/14651858.CD001417.pub2"},{"key":"7606_CR9","doi-asserted-by":"publisher","unstructured":"Kang JM, Cho YS, Park S, Lee BH, Sohn BK, Choi CH, Choi JS, Jeong HY, Cho SJ, Lee JH, Lee JY (2018) Montreal cognitive assessment reflects cognitive reserve. BMC Geriatr 18(1). https:\/\/doi.org\/10.1186\/s12877-018-0951-8","DOI":"10.1186\/s12877-018-0951-8"},{"issue":"12","key":"7606_CR10","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1046\/j.1528-1157.2001.32101.x","volume":"42","author":"EH Kossoff","year":"2001","unstructured":"Kossoff EH, Bergey GK, Freeman JM, Vining EPG (2001) Levetiracetam Psychosis in Children with Epilepsy. Epilepsia 42(12):1611\u20131613. https:\/\/doi.org\/10.1046\/j.1528-1157.2001.32101.x","journal-title":"Epilepsia"},{"issue":"9","key":"7606_CR11","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1212\/WNL.56.9.1177","volume":"56","author":"KJ Meador","year":"2001","unstructured":"Meador KJ, Loring DW, Ray PG, Murro AM, King DW, Perrine KR, Vazquez BR, Kiolbasa T (2001) Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology 56(9):1177\u20131182. https:\/\/doi.org\/10.1212\/WNL.56.9.1177","journal-title":"Neurology"},{"key":"7606_CR12","doi-asserted-by":"publisher","unstructured":"Novak A, Vizjak K, Gacnik A, Rakusa M (2022) Cognitive impairment in people with epilepsy: Montreal Cognitive Assessment (MoCA) as a screening tool. Acta Neurol Belgica. https:\/\/doi.org\/10.1007\/s13760-022-02046-4","DOI":"10.1007\/s13760-022-02046-4"},{"key":"7606_CR13","doi-asserted-by":"publisher","unstructured":"Ogunjimi L, Yaria J, Makanjuola A, Alabi A, Osalusi B, Oboh D, Olusola-Bello M, Aderinola A, Ogunniyi A (2021) Cognitive dysfunction in Nigerian women with epilepsy on carbamazepine and levetiracetam monotherapy. Brain Behav 11(4). https:\/\/doi.org\/10.1002\/brb3.2038","DOI":"10.1002\/brb3.2038"},{"issue":"7","key":"7606_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/BF03343601","volume":"22","author":"M Ozata","year":"1999","unstructured":"Ozata M, Odabasi Z, Caglayan S, Beyhan Z, Vural O, Ozdemir C (1999) Event-related brain potentials in male hypogonadism. J Endocrinol Invest 22(7):508\u2013513. https:\/\/doi.org\/10.1007\/BF03343601","journal-title":"J Endocrinol Invest"},{"key":"7606_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jocn.2018.10.134","volume":"59","author":"B \u00d6zt\u00fcrk","year":"2019","unstructured":"\u00d6zt\u00fcrk B, \u00d6v\u00fcn\u00e7 \u00d6z\u00f6n A, Karada\u015f \u00d6 (2019) Evaluation of cognitive functions in migraineurs treated with topiramate. J Clin Neurosci 59:89\u201392. https:\/\/doi.org\/10.1016\/j.jocn.2018.10.134","journal-title":"J Clin Neurosci"},{"key":"7606_CR16","doi-asserted-by":"publisher","unstructured":"Quon RJ, Mazanec MT, Schmidt SS, Andrew AS, Roth RM, MacKenzie TA, Sajatovic M, Spruill T, Jobst BC (2020) Antiepileptic drug effects on subjective and objective cognition. Epilepsy Behav 104. https:\/\/doi.org\/10.1016\/j.yebeh.2020.106906","DOI":"10.1016\/j.yebeh.2020.106906"},{"key":"7606_CR17","doi-asserted-by":"publisher","unstructured":"\u0160ari\u0107 Juri\u0107 J (2021) Effect of antiepileptic drugs on P300 event-related potentials in patients with epilepsy. Acta Clinica Croatica. https:\/\/doi.org\/10.20471\/acc.2021.60.s3.05","DOI":"10.20471\/acc.2021.60.s3.05"},{"issue":"2","key":"7606_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1528-1157.1993.tb02417.x","volume":"34","author":"D Smith","year":"1993","unstructured":"Smith D, Baker G, Davies G, Dewey M, Chadwick DW (1993) Outcomes of Add-on Treatment with Lamotrigine in Partial Epilepsy. Epilepsia 34(2):312\u2013322. https:\/\/doi.org\/10.1111\/j.1528-1157.1993.tb02417.x","journal-title":"Epilepsia"},{"issue":"2","key":"7606_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1053\/seiz.1998.0234","volume":"8","author":"A Soysal","year":"1999","unstructured":"Soysal A, Atakli D, Atay T, Altintas H, Baybas S, Arpaci B (1999) Auditory event- related potentials (P300) in partial and generalized epileptic patients. Seizure 8(2):107\u2013110","journal-title":"Seizure"},{"issue":"1","key":"7606_CR20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4103\/0972-6748.57865","volume":"18","author":"S Sur","year":"2009","unstructured":"Sur S, Sinha V (2009) Event-related potential: An overview. Indust Psychiatr J 18(1):70. https:\/\/doi.org\/10.4103\/0972-6748.57865","journal-title":"Indust Psychiatr J"},{"key":"7606_CR21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","volume-title":"The Lancet","author":"RD Thijs","year":"2019","unstructured":"Thijs, R. D., Surges, R., O\u2019Brien, T. J., & Sander, J. W. (2019). Epilepsy in adults. In The Lancet (Vol. 393, Issue 10172, pp. 689\u2013701). Lancet Publishing Group. https:\/\/doi.org\/10.1016\/S0140-6736(18)32596-0"},{"issue":"2","key":"7606_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/WNF.0b013e318285f3da","volume":"36","author":"Y Tumay","year":"2013","unstructured":"Tumay Y, Altun Y, Ekmekci K, Ozkul Y (2013) The effects of levetiracetam, carbamazepine, and sodium valproate on P100 and P300 in epileptic patients. Clin Neuropharmacol 36(2):55\u201358. https:\/\/doi.org\/10.1097\/WNF.0b013e318285f3da","journal-title":"Clin Neuropharmacol"},{"key":"7606_CR23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1528-1167.2010.02806.x","volume":"51","author":"JA Witt","year":"2010","unstructured":"Witt JA, Helmstaedter C (2010) The impact of antiepileptic drug treatment on attention and executive functions. Epilepsia 51:20","journal-title":"Epilepsia"},{"issue":"3700","key":"7606_CR24","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1126\/science.150.3700.1187","volume":"150","author":"S Sutton","year":"1965","unstructured":"Sutton S, Braren M, Zubin J, John ER (1965) Evoked-potential correlates of stimulus uncertainty. Science 150(3700):1187\u20138. https:\/\/doi.org\/10.1126\/science.150.3700.1187","journal-title":"Science"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07606-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07606-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07606-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T13:26:18Z","timestamp":1727184378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07606-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["7606"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07606-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"19 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflict of interest among the authors in the conduct of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}